CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.
OBJECTIVE
To determine if circulating CD4+ lymphocyte counts are predictive of specific infectious or neoplastic processes causing pulmonary dysfunction.


METHODS
Retrospective, consecutive sample study.


METHODS
Referral-based clinic and wards.


METHODS
We studied 100 patients infected with human immunodeficiency virus (HIV) who had had 119 episodes of pulmonary dysfunction within 60 days after CD4 lymphocyte determinations.


RESULTS
Circulating CD4 counts were less than 0.200 X 10(9) cells/L (200 cells/mm3) before 46 of 49 episodes of pneumocystis pneumonia, 8 of 8 episodes of cytomegalovirus pneumonia, and 7 of 7 episodes and 19 of 21 episodes of infection with Cryptococcus neoformans and Mycobacterium avium-intracellulare, respectively. In contrast, circulating CD4 counts before episodes of nonspecific interstitial pneumonia were quite variable: Of 41 episodes, 11 occurred when CD4 counts were greater than 0.200 X 10(9) cells/L. The percent of circulating lymphocytes that were CD4+ had a predictive value equal to that of CD4 counts. Serum p24 antigen levels had no predictive value.


CONCLUSIONS
Pneumocystis pneumonia, cytomegalovirus pneumonia, and pulmonary infection caused by C. neoformans or M. avium-intracellulare are unlikely to occur in HIV-infected patients who have had a CD4 count above 0.200 to 0.250 X 10(9) cells/L (200 to 250 cells/mm3) or a CD4 percent above 20% to 25% in the 60 days before pulmonary evaluation. Patients infected with HIV who have a CD4 count below 0.200 X 10(9) cells/L (or less than 20% CD4 cells) are especially likely to benefit from antipneumocystis prophylaxis.
Masur
H
H
National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
Ognibene
F P
FP
Yarchoan
R
R
Shelhamer
J H
JH
Baird
B F
BF
Travis
W
W
Suffredini
A F
AF
Deyton
L
L
Kovacs
J A
JA
Falloon
J
J
D003453:Cryptococcosis / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000276:immunology; D015488:HIV Antigens / Q000032:analysis; D016655:HIV Core Protein p24; D006679:HIV Seropositivity / Q000150:complications / Q000276:immunology*; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000276:immunology; D015270:Mycobacterium avium-intracellulare Infection / Q000276:immunology; D009894:Opportunistic Infections / Q000209:etiology / Q000276:immunology*; D011014:Pneumonia / Q000209:etiology / Q000276:immunology*; D011020:Pneumonia, Pneumocystis / Q000276:immunology; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012191:Retroviridae Proteins / Q000032:analysis; D012514:Sarcoma, Kaposi / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer
D015488:HIV Antigens; D016655:HIV Core Protein p24; D012191:Retroviridae Proteins